GlassScriptPhysician profile
Leandra Berrios
NPI 1982154159
$4,631.31
in general payments reported to CMS, 2019-2025
23 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $993 · 2022: $1,295 · 2023: $1,195 · 2024: $635 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $890.42 | 2021-2025 | Jemperli, Zejula |
| Seagen INC. | $433.56 | 2022-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $382.17 | 2021-2023 | Myrisk |
| Eisai INC. | $378.86 | 2021-2024 | |
| Abbvie INC. | $343.53 | 2021-2024 | |
| Astellas Pharma US INC | $304.16 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $249.68 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $248.68 | 2022-2025 | Tecvayli, Darzalex, Carvykti |
| Merck Sharp & Dohme LLC | $221.79 | 2022-2024 | Keytruda, Lynparza |
| Ethicon US, LLC | $158.29 | 2021-2023 | Echelon Circular, Stratafix, Vistaseal |
| Genentech USA, INC. | $143.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.93 | 2022 | |
| Genmab U.S., INC. | $121.87 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2024 | Libtayo |
| Agios Pharmaceuticals, INC. | $121.60 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $97.76 | 2023 | Elahere |
| Celgene Corporation | $91.66 | 2021 | |
| Sumitomo Pharma America, INC. | $66.74 | 2023-2025 | Myfembree, Gemtesa |
| Daiichi Sankyo INC. | $58.93 | 2025 | Datroway, Enhertu |
| Hologic Sales and Service, LLC | $20.29 | 2025 | Aptima, Thinprep 2000 Processor |
| Incyte Corporation | $17.25 | 2025 | Niktimvo |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
| Clovis Oncology, INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandra Berrios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.